Chest
Recent Advances in Chest MedicineUpdate on the Management of COPD
Section snippets
COPD Is Highly Prevalent, Underdiagnosed, Undertreated, and Underperceived
COPD affects millions of individuals, limits the functional capacity of many, and has become an important cause of death worldwide. Although preventable, COPD has a long subclinical phase. The previously accepted thought that COPD develops in only 15% of smokers is an underestimation of the actual number that is now known to be much larger. Once dyspnea develops, it occurs at ever lower levels of exercise. With disease progression, gas exchange becomes compromised and patients may have
COPD, a Multicomponent Disease
The airflow obstruction of COPD, as expressed by FEV1, is by definition only partially reversible.1, 2 In a paradoxical way, this defining physiology has been used as the outcome to determine the effectiveness of interventions. It is no surprise that the lack of large response in FEV1 to different therapies17, 18, 19, 20, 21, 22, 23, 24, 25, 26 has resulted in an undeserved nihilism. There is increasing evidence that independent of the degree of airflow obstruction, lung volumes are important
COPD, a Treatable Disease
Current evidence suggests that smoking cessation,6 long-term oxygen therapy in hypoxemic patients,42, 43 noninvasive mechanical ventilation in some patients with acute-on-chronic respiratory failure,44, 45, 46 and LVRS for patients with upper-lobe emphysema and poor exercise capacity47 improve survival. The TORCH (Towards a Revolution in COPD Health) study48 of >6,000 patients showed that the combination of salmeterol and fluticasone not only improved lung function and health status, but that
Therapy Is Effective for the Respiratory Manifestations of COPD
Once COPD is diagnosed, the patient should be encouraged to actively participate in disease management. This concept of “collaborative management” may improve self-reliance and esteem. All patients should be encouraged to lead a healthy lifestyle and exercise regularly. Preventive care is extremely important at this time, and all patients should receive immunizations including pneumococcal vaccine and yearly influenza vaccinations.1, 3 This comprehensive approach is summarized as a proposal in
Smoking Cessation and Decreased Exposure to Biomass Fuel Combustion Fumes
As smoking is the major cause of COPD, smoking cessation is the most important component of therapy for patients who still smoke.1, 3 Because secondhand smoking is known to damage lung function, limitation of exposure to involuntary smoke, particularly in children, should be encouraged. The factors that cause patients to smoke include the addictive potential of nicotine; conditional responses to stimuli surrounding smoking; psychosocial problems such as depression, poor education, and low
Pharmacologic Therapy of Airflow Obstruction
Many patients with COPD require pharmacologic therapy. This should be organized according to the severity of symptoms (dyspnea and functional capacity), the degree of lung dysfunction, and the tolerance to specific drugs.1, 3 A step-wise approach similar in concept to that developed for systemic hypertension may be helpful because medications alleviate symptoms, improve exercise tolerance and quality of life, and may decrease mortality. Table 1, Table 2 provide a summary of the evidence
Therapies That Are Effective for the Nonrespiratory Manifestations of COPD
The most exciting changes in the way we conceptualize COPD is the recognition of the extrapulmonary manifestations of COPD.5, 111, 112 Some of the most important advances in the therapy of COPD center on our capacity to impact on the disease without having to necessarily alter lung function. Two of the proven forms of therapy for COPD fall within this category: pulmonary rehabilitation and oxygen therapy. If we add mechanical ventilation during exacerbations, the field is wide open to explore
Pulmonary Rehabilitation
Pulmonary rehabilitation is an essential component of the comprehensive management of patients with symptomatic COPD.1, 2, 113, 114, 115, 116, 117, 118, 119, 120 Patients with moderate-to-moderately severe disease are the best candidates for treatment, for whom the disabling effects of end-stage respiratory failure can be prevented. The rehabilitation program should have resources available to teach and supervise respiratory therapy techniques such as oxygen, use of inhalers and nebulizers,
Supplemental Oxygen Therapy
The results of the Nocturnal Oxygen Therapy Trial42 and Medical Research Council study43 showed that supplemental oxygen improves survival in patients with hypoxemic COPD. Other beneficial effects of long-term oxygen include reductions in polycythemia, pulmonary artery pressures, dyspnea, hypoxemia during sleep, and reduced nocturnal arrhythmias. Importantly, oxygen can also improve neuropsychiatric testing124, 125 and exercise tolerance.126, 127, 128 Oxygen supplementation to patients who
Exacerbations
An exacerbation is an event in the natural course of the COPD characterized by a change in the patient's baseline dyspnea, cough, and/or sputum beyond day-to-day variability sufficient to warrant a change in management.1, 3, 129, 130 Care must be taken to rule out heart failure, myocardial infarction, arrhythmias, and pulmonary embolism, all of which may present with clinical signs and symptoms similar to exacerbation of COPD. An algorithm describing a rational approach to exacerbations is
Conclusion
Over the years, our knowledge about COPD and the capacity to treat it have increased significantly. We now know that COPD is not just a disease affecting the lungs,140 but that it has important systemic consequences.141 Smoking cessation campaigns have resulted in a decrease in smoking prevalence in the United States. Similar efforts in the rest of the world should have the same impact. The widespread application of long-term oxygen therapy for hypoxemic patients has resulted in increased
References (141)
- et al.
Prevalence of chronic obstructive pulmonary disease in five Latin American cities: the PLATINO study
Lancet
(2005) - et al.
Prevalence of COPD in Greece
Chest
(2004) - et al.
Diagnostic labeling of COPD in five Latin American cities
Chest
(2007) - et al.
Efficacy of salmeterol xinoafate in the treatment of COPD
Chest
(1999) - et al.
Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD
Chest
(1999) - et al.
Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD
Chest
(2002) - et al.
Impact of COPD exacerbations on patient-centered outcomes
Chest
(2007) - et al.
Improvement of inspiratory capacity and hyperinflation with tiotropium in COPD patients with severe hyperinflation
Chest
(2003) - et al.
Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD
Chest
(2006) - et al.
Salmeterol reduces dyspnea and improves lung function in patients with COPD
Chest
(1997)
A comparison of inhaled ipratropium, oral theophylline plus inhaled β-agonist, and the combination of all three in patients with COPD
Chest
Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase
Lancet
Roflumilast, an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial
Lancet
Cilomilast for COPD: results of a 6-month, placebo controlled study of a potent, selective inhibitor of posphodiesterase 4
Chest
Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study
Chest
Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised trial
Lancet
Inhaled combination therapy with inhaled long-acting β2-agonist and corticosteroids in stable COPD
Chest
The National Mucolytic Study: results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis
Chest
Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial
Lancet
Relationship of sputum color to nature and outpatient management of acute exacerbation of COPD
Chest
Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD
Chest
Reduction pneumoplasty for giant bullous emphysema: implications for surgical treatment of nonbullous emphysema
Chest
Cardiopulmonary exercise testing following allogeneic lung transplantation for different underlying disease states
Chest
The registry of the International Society for Heart and Lung Transplantation: eighteenth official report-2001
J Heart Lung Transplant
International guidelines for the selection of lung transplant candidates: 2006 update; a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation
J Heart Lung Transplant
Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema
J Thorac Cardiovasc Surg
Correlation of changes in quality of life after lung volume reduction surgery with changes in lung function, exercise, and gas exchange
Chest
Standards for the diagnosis and treatment of COPD
Eur Respir J
Global Obstructive Lung Disease Initiative, updated 2006
Standards for the diagnosis and case of patients with chronic obstructive pulmonary disease
Am J Respir Crit Care Med
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary
Am J Respir Crit Care Med
The body mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease
N Engl J Med
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial
Ann Intern Med
Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee
Thorax
Chronic obstructive pulmonary disease surveillance: United States, 1971–2000
MMWR Morb Mortal Wkly Rep
Population impact of different definitions of airways obstruction
Eur Respir J
Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study
Chest
An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages
Thorax
Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure
Respir Care
Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey
Eur Respir J
Effect of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study
JAMA
A long term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
Eur Respir J
Quality of life changes in COPD patients treated with salmeterol
Am J Respir Crit Care Med
Improved health outcome in patients with COPD during 1 year treatment with tiotropium
Eur Respir J
Salmeterol plus theophylline combination therapy in the treatment of COPD
Chest
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial
BMJ
Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease
N Engl J Med
Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease
Eur Respir J
Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease
Am J Respir Crit Care Med
Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease
Am J Respir Crit Care Med
Cited by (0)
The author has no conflict of interest to disclose.
Reproduction of this article is prohibited without written permission from the American College of chest Physicians (www.chestjournal.org/misc/rerints.shtml).